Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01193491 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation of IPI-493 in Hematologic Malignancies
A Phase 1 study, sponsored by Infinity Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01193491: Clinical Trial Phase 1 study, sponsored by Infinity Pharmaceuticals.
NCT01193491 is a Phase 1 study that was terminated before completion, run by Infinity Pharmaceuticals. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01193491, a Phase 1 study, was terminated before completion, sponsored by Infinity Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.
Primary Outcome
Safety Endpoints * The incidence of reported adverse events (AEs), serious adverse events (SAEs), concomitant medication use, laboratory test results, electrocardiogram (ECG) results, Eastern Cooperative Oncology Group (ECOG) performance status results, and vital sign results * Maximum tolerated dose, defined as the dose level below the dose at which ≥33% of patients experience a dose limiting toxicity (DLT) Pharmacodynamic Endpoints
Interventions
- DRUG IPI-493
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Why NCT01193491 stopped before completion
NCT01193491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which IPI-493 is the first listed.
NCT01193491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01193491 about?
NCT01193491 is a clinical study titled "Dose Escalation of IPI-493 in Hematologic Malignancies". The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.
What is the current status of trial NCT01193491?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2010-06. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01193491?
The interventions under investigation include: IPI-493 (DRUG).
Who is sponsoring clinical trial NCT01193491?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01193491's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia